RT Journal
A1 Hennekens CH, DeMets D
T1 THe need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses
JF JAMA
JO JAMA
YR 2009
FD December 2
VO 302
IS 21
SP 2361
OP 2362
DO 10.1001/jama.2009.1756
UL http://dx.doi.org/10.1001/jama.2009.1756
AB 
Randomized trials of adequate size and duration designed to test a priori hypotheses represent the most reliable design strategy to detect the most realistically small to moderate therapeutic effects of drugs. Such trials should achieve high adherence to an adequate dose of the drug and a sufficient number of clinical end points to distinguish reliably between the null hypothesis and the most plausible alternative hypothesis of small to moderate benefit or harm.1 With regard to the development of drugs to treat diabetes mellitus, the US Food and Drug Administration (FDA) has developed guidance for industry that somewhat overemphasizes results from meta-analyses of phase 2 trials that were not large enough to test realistic hypotheses about clinical cardiovascular (CV) events.2 Even in aggregate, such results should be considered more as hypothesis formulating than as hypothesis testing. The main need now is for trials that are large enough to have adequate statistical power.